CD44 and endometrial cancer: In vitro studies using breast and endometrial cancer cell lines revealed that hormonal treatments, such as estradiol, tamoxifen, and GnRH analogs, modulated solCD44 levels variably, suggesting hormone-specific regulation of CD44 isoform secretion and a complex relationship with therapeutic response [87].